New Lenox Park District Board Approves 2025-2026 Budget
NEW LENOX – The New Lenox Community Park District Board of Commissioners unanimously approved the budget and appropriation ordinance for the 2025-2026 fiscal year during its regular meeting on June 18.
The passage of Ordinance #25-05-01 marks the culmination of the district’s annual budget process. The vote followed a formal public hearing held at 6:00 p.m., just prior to the board’s regular session at the Village Hall. No members of the public offered comments during the hearing.
According to a public notice issued on June 13, copies of the proposed budget were made available to the community for review starting May 23. Residents could request a copy from Guest Services Supervisor Melissa McGrath.
At the meeting, Board President Schulz called for any final questions or comments on the ordinance from the commissioners. Hearing none, he requested a motion for its approval. The motion was made by Commissioner Kraemer and seconded by Commissioner Fischer, passing with a unanimous voice vote.
The approved ordinance will guide the park district’s spending and financial operations from the start of the new fiscal year, funding everything from park maintenance and recreational programming to capital projects and staff salaries.
Latest News Stories
Illinois Quick Hits: Fuel price drops below $4.25, still higher than in 2025
California’s billionaire tax officially heads to Nov. 3 ballot
Los Angeles County on track to raise sales tax to 10.25%
EXCLUSIVE: Individual targeted in foiled UFC terror plot speaks out
Disability-rights advocates sue Illinois over physician-assisted suicide law
Supreme Court backs gun rights for marijuana users in 9-0 decision
Iran deal omits terror proxies, ballistic missiles, human rights
‘No kings’ at $830 million Obama Center opening
Alleged UFC White House ringleader was in US illegally
‘Policy blunder’ or ‘pathway to peace’: Republicans divided over Iran deal
Second produced water treatment pilot facility online in Permian Basin
Bill provides access to customized gene therapies, medicines